Lupin recalling antibiotic produced at plant cited by FDA

Multiple syringes

India’s Lupin is recalling nearly 54,000 vials of an antibiotic made at its plant in Mandideep, India. It turns out that it is one of the facilities to receive citations during an inspection this year by the FDA.

According to the most recent FDA Enforcement Report, Lupin is recalling 53,902 vials of injected ceftriaxone because the drug was manufactured using active pharmaceutical ingredients whose intermediates failed specifications. The recall actually began in March but was just posted by the FDA after being deemed a Class III. 

In March, Lupin reported in a filing with the Bombay Stock Exchange that it had received four observations for two plants at its Mandideep site following a two-week inspection by the FDA in February. Lupin, who referred to the citations as "minor in nature," said one of the observations had to do with the use of a "non-conforming" intermediate.  

Lupin last year also received a Form 483 with 9 observations for a plant in Goa, and the year before the FDA cited a facility in Indore with half a dozen.

Lupin, which claims to be one of the fastest-growing generics companies selling in the U.S., earlier this year completed a $900 million deal to buy New Jersey-based Gavis Pharmaceuticals. Lupin picked up in the deal a 45,000-square-foot manufacturing and R&D site and a 124,000-square-foot packaging and distribution operation in Somerset, NJ. It also got a portfolio of 120 marketed products and 62 ANDA filings.

Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This on-demand webinar discusses the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

- access the recalls here 

Related Articles: 
FDA cites Lupin Indian facilities for what drugmaker calls 'minor' issues 
Lupin gets first U.S. manufacturing base with buyout of GAVIS

Suggested Articles

The FDA has lambasted the Torrent Pharmaceuticals in a warning letter for making OTC meds using water tainted with bacteria.

Eli Lilly is investing $400 million in its Indianapolis site to expand production of insulin and other diabetes meds, and add 100 jobs.

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.